Phaseline

Companies › IVIEW Therapeutics

IVIEW Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GVB-2001
Self-complementary adeno-associated viral vector (scAAV) delivering dominant-negative RhoA
RHOAPhase 1Primary Open-Angle Glaucoma (POAG)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06921317GVB-2001Phase 1Primary Open-Angle Glaucoma (POAG)OphthalmologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

RHOA (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.